Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) Growth (1y) (2010 - 2026)
Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
251.11% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-13.31% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
102.51% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-79.34% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-103.05% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
61.45% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
-43.16% |
| Date | Value |
|---|
| Mar 31, 2026 |
-43.16% |
| Dec 31, 2025 |
-136.92% |
| Sep 30, 2025 |
-129.09% |
| Jun 30, 2025 |
123.64% |
| Mar 31, 2025 |
106.52% |
| Dec 31, 2024 |
550.00% |
| Sep 30, 2024 |
161.90% |
| Jun 30, 2024 |
89.66% |
| Mar 31, 2024 |
70.37% |
| Dec 31, 2023 |
7,688.88% |
| Sep 30, 2023 |
625.00% |
| Jun 30, 2023 |
93.33% |
| Mar 31, 2023 |
-57.14% |
| Dec 31, 2022 |
99.59% |
| Sep 30, 2022 |
80.00% |
| Jun 30, 2022 |
114.29% |
| Mar 31, 2022 |
600.00% |
| Dec 31, 2021 |
-390.91% |
| Sep 30, 2021 |
-104.99% |
| Jun 30, 2021 |
143.75% |
